Zydus, Sun Pharma Co-market Oral Drug for Kidney Diseases

Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited (Sun Pharma) have entered into a license agreement for the joint marketing of a new drug for anemia associated with kidney disease. Desidustat is the first oral drug of its kind to treat anemia associated with chronic kidney disease (CKD) in India, the drug makers said. Under the terms of the agreement, Zydus has granted semi-exclusive rights to Sun Pharma to co-market the product in India under the brand name RYTSTAT. Zydus launched the drug under the brand name Oxemia in 2022 and continues to market it.

Zydus receives an initial license fee and revenue based on the achievement of predefined milestones. "Desidustat, one of the critical treatment options for patients with chronic diseases, has greatly improved the quality of life of patients due to the ease of taking an oral pill instead of an injection. We are pleased to join hands with Sun Pharma to expand this new medicine, providing access to more patients," said a spokesperson for Zydus Lifesciences Ltd. Kirti Ganorkar, Chief Business Officer, India, Sun Pharma, said, "This partnership will enable better access to critical care, helping millions of CKD patients." Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic drug company in the world with global revenue of over $5.1 billion. With the support of more than 40 manufacturing facilities, we provide high-quality, affordable medicines that are trusted by healthcare professionals and patients in more than 100 countries around the world.